PANews, August 21 news, according to the SEC official announcement, Windtree Therapeutics (WINT) has been decided by Nasdaq to suspend trading of its common stock and initiate delisting procedures starting from the market open on August 21, 2025, due to failure to comply with Nasdaq listing rule 5550(a)(2). The company's stock will be transferred to OTC market trading, with the code remaining WINT. Windtree Therapeutics has applied for listing on the OTC Markets, but approval is not guaranteed. The company's business and operations will not be affected and will continue to submit regular reports to the SEC.

Last month, it was reported that the listed company Windtree announced it had obtained $520 million in new financing to expand its BNB capital strategy.